Skip to main content

Table 3 Relationship between PLRs and clinical factors

From: An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer

Factor

pPLR (+)

pPLR (−)

P-value

iPLR (+)

iPLR (−)

P-value

fPLR (+)

fPLR (−)

P-value

Sex(M/F)

32/18

41/ 9

0.070

39/11

34/16

0.368

24/11

49/16

0.486

Age (< 65/≥65 years)

24/26

17/33

0.222

21/29

20/30

1.000

15/20

26/39

0.833

Tumor size (< 60/≥60 mm)

21/29

27/23

0.317

26/24

22/28

0.548

15/20

33/32

0.531

Histologic type (Diff/Undiff)

15/35

20/30

0.402

19/31

16/34

0.675

8/27

27/38

0.080

pT (1/2/3/4)

0/ 6/16/28

5/ 6/25/14

0.006*

4/ 8/21/17

1/ 4/20/25

0.210

3/ 5/11/16

2/ 7/30/26

0.393

pN (0/1/2/3)

4/13/12/21

10/12/19/ 9

0.030

8/15/16/11

6/10/15/19

0.332

4/ 6/13/12

10/19/18/18

0.480

pStage (II/III)

12/38

27/23

0.004*

25/25

14/36

0.040

13/22

26/39

0.832

Lymphatic invasion (+/−)

42/ 8

38/12

0.454

39/11

41/ 9

0.803

26/ 9

54/11

0.307

Venous invasion (+/−)

39/11

39/11

1.000

38/12

40/10

0.810

25/10

53/12

0.312

Recurrence (+/−)

19/31

16/34

0.675

14/36

21/29

0.208

15/20

20/45

0.274

Outcome (D/A)

16/34

8/42

0.100

10/40

14/36

0.483

14/21

10/55

0.013

  1. M, male; F, female; Diff, differentiated type; Undiff, undifferentiated type; pT, pN, pStage = pathological T stage, N stage. Pathological cancer stage according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual; pPLR, preoperative platelet-to-lymphocyte ratio; iPLR, the ratio of the PLR on the initial day of adjuvant chemotherapy to pPLR; fPLR, the ratio of the PLR on the final day of adjuvant chemotherapy to iPLR; D/A, dead or alive; *P-value indicates statistical significance after false discovery rate correction
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us